Skip to content

The safety and effectiveness of intravenous lidocaine in painless gastrointestinal endoscopy

Safety and effectiveness of intravenous lidocaine in painless gastrointestinal endoscopy

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053818
Enrollment
Unknown
Registered
2021-11-30
Start date
2021-12-06
Completion date
Unknown
Last updated
2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

control group:sufentanil+midazolam +isometric saline+propofol
lidocaine group:sufentanil+midazolam+lidocaine+propofol

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-65 years who are going to undergo painless gastrointestinal endoscopy, no gender limitation; 2. ASA classification (American Society of Anesthesiologists classification) is I-III grade; 3. After preoperative anesthesia outpatient evaluation, patients who can undergo painless gastrointestinal endoscopy under general anesthesia; 4. Heart rate > 50 beats/min and no previous atrioventricular block; 5. Good liver and kidney function; 6. Patients who have not used local anesthetics in the past 1 week; 7. BMI < 30kg/m^2; 8. Voluntarily participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who have participated in other clinical trials within the past four weeks; 2. Patients allergic to lidocaine; 3. Patients who cannot understand the VAS score and cannot score; 4. Pregnant patients, puerperae, patients with positive urine pregnancy test; 5. Patients who have used analgesics and hypnotics in the past week; 6. Complicated with severe central nervous system disease and severe mental illness before surgery; 7. Patients who are deemed unsuitable for participation in this study by the investigator.

Design outcomes

Primary

MeasureTime frame
the incidence of hypoxemia;

Secondary

MeasureTime frame
the incidence of body movement;

Countries

China

Contacts

Public ContactAn Lixin

Beijing Friendship Hospital, Capital Medical University

anlixin8120@163.com+86 13810248120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026